|
US4410545A
(en)
*
|
1981-02-13 |
1983-10-18 |
Syntex (U.S.A.) Inc. |
Carbonate diester solutions of PGE-type compounds
|
|
US4621100A
(en)
*
|
1981-09-25 |
1986-11-04 |
The Upjohn Company |
Treatment of osteoporosis with prostaglandins
|
|
AU1695783A
(en)
*
|
1982-07-19 |
1984-01-26 |
Syntex (U.S.A.) Inc. |
Encapsulated pge type compositions
|
|
US4792617A
(en)
*
|
1984-07-31 |
1988-12-20 |
Syntex (U.S.A.) Inc. |
11-substituted-16-phenoxy and 16-substituted phenoxy-prostatrienioc acid derivatives
|
|
DK606185A
(da)
*
|
1984-12-24 |
1986-06-25 |
Syntex Inc |
Prostaglandinderivater
|
|
US5962490A
(en)
|
1987-09-25 |
1999-10-05 |
Texas Biotechnology Corporation |
Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
|
|
US4954346A
(en)
*
|
1988-06-08 |
1990-09-04 |
Ciba-Geigy Corporation |
Orally administrable nifedipine solution in a solid light resistant dosage form
|
|
US6342610B2
(en)
|
1993-05-20 |
2002-01-29 |
Texas Biotechnology Corp. |
N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
|
|
US5595563A
(en)
*
|
1995-09-05 |
1997-01-21 |
Moisdon; Roger G. F. |
Method and apparatus for maintaining the position of body parts
|
|
AP9901643A0
(en)
|
1997-04-28 |
1999-10-02 |
Texas Biotechnology Corp |
Sulfonamides for treatment of endothelin-mediated disorders.
|
|
US5783705A
(en)
|
1997-04-28 |
1998-07-21 |
Texas Biotechnology Corporation |
Process of preparing alkali metal salys of hydrophobic sulfonamides
|
|
US6362009B1
(en)
|
1997-11-21 |
2002-03-26 |
Merck & Co., Inc. |
Solid phase synthesis of heterocycles
|
|
US7169410B1
(en)
*
|
1998-05-19 |
2007-01-30 |
Sdg, Inc. |
Targeted liposomal drug delivery system
|
|
US6638977B1
(en)
|
1999-11-19 |
2003-10-28 |
Corvas International, Inc. |
Plasminogen activator inhibitor antagonists
|
|
WO2001036351A2
(en)
|
1999-11-19 |
2001-05-25 |
Corvas International, Inc. |
Plasminogen activator inhibitor antagonists related applications
|
|
US7897140B2
(en)
*
|
1999-12-23 |
2011-03-01 |
Health Research, Inc. |
Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
|
|
JP2003021130A
(ja)
*
|
2001-07-09 |
2003-01-24 |
Chuo Spring Co Ltd |
押し引きコントロールケーブル
|
|
CA2463724A1
(en)
*
|
2001-10-16 |
2003-04-24 |
Structural Bioinformatics Inc. |
Organosulfur inhibitors of tyrosine phosphatases
|
|
AUPR868201A0
(en)
*
|
2001-11-05 |
2001-11-29 |
Thorlock International Limited |
Q-factor switching method and apparatus for detecting nuclear quadrupole and nuclear magnetic resonance signals
|
|
US7482366B2
(en)
|
2001-12-21 |
2009-01-27 |
X-Ceptor Therapeutics, Inc. |
Modulators of LXR
|
|
AU2002367060A1
(en)
*
|
2001-12-21 |
2003-07-30 |
X-Ceptor Therapeutics, Inc. |
Heterocyclic modulators of nuclear receptors
|
|
WO2003059884A1
(en)
|
2001-12-21 |
2003-07-24 |
X-Ceptor Therapeutics, Inc. |
Modulators of lxr
|
|
US20040001801A1
(en)
*
|
2002-05-23 |
2004-01-01 |
Corvas International, Inc. |
Conjugates activated by cell surface proteases and therapeutic uses thereof
|
|
EP1517684B1
(de)
|
2002-06-27 |
2009-07-22 |
Health Research, Inc. |
Fluorinierte chlorin und bacteriochlorin photosensitizer für fotodynamische therapie
|
|
WO2004005289A2
(en)
*
|
2002-07-02 |
2004-01-15 |
Health Research, Inc. |
Efficient synthesis of pyropheophorbide a and its derivatives
|
|
ES2532399T3
(es)
|
2003-03-05 |
2015-03-26 |
Halozyme, Inc. |
Glicoproteína hialuronidasa soluble (sHASEGP), proceso para prepararla, usos y composiciones farmacéuticas que la comprenden
|
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
|
US20090123367A1
(en)
*
|
2003-03-05 |
2009-05-14 |
Delfmems |
Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
|
|
JP4847868B2
(ja)
*
|
2003-05-14 |
2011-12-28 |
ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド |
化合物、及び、アミロイドベータの調節におけるその使用
|
|
US7652044B2
(en)
*
|
2003-06-03 |
2010-01-26 |
Novartis A.G. |
P-38 inhibitors
|
|
US7057100B2
(en)
*
|
2003-06-26 |
2006-06-06 |
The J.C. Robinson Seed Co. |
Inbred corn line W23129
|
|
EP1911754B1
(de)
|
2003-08-13 |
2013-10-09 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl-Peptidase-Hemmer
|
|
US20050203184A1
(en)
|
2003-09-10 |
2005-09-15 |
Petasis Nicos A. |
Benzo lipoxin analogues
|
|
US7420000B2
(en)
|
2003-09-10 |
2008-09-02 |
University Of Southern California |
Amino phosphonate and amino bis-phosphonate derivatives
|
|
WO2005033092A1
(en)
|
2003-09-19 |
2005-04-14 |
Galileo Pharmaceuticals, Inc. |
Chroman derivatives
|
|
US20050148534A1
(en)
*
|
2003-09-22 |
2005-07-07 |
Castellino Angelo J. |
Small molecule compositions and methods for increasing drug efficiency using compositions thereof
|
|
WO2005090370A1
(en)
*
|
2004-02-05 |
2005-09-29 |
The Regents Of The University Of California |
Pharmacologically active agents containing esterified phosphonates and methods for use thereof
|
|
US8519158B2
(en)
|
2004-03-12 |
2013-08-27 |
Ligand Pharmaceuticals Incorporated |
Androgen receptor modulator compounds and methods
|
|
KR20070032700A
(ko)
|
2004-05-20 |
2007-03-22 |
폴드알엑스 파마슈티칼스, 인크. |
트랜스티레틴을 안정화하고 트랜스티레틴 미스폴딩을억제하기 위한, ２-((헤테로)아릴)-벤즈옥사졸 화합물 및유도체, 그리고 조성물 및 방법
|
|
EP1765332A2
(de)
*
|
2004-06-17 |
2007-03-28 |
Cengent Therapeutics, Inc. |
Trisubstituierte stickstoffmodulatoren von tyrosin-phosphatasen
|
|
WO2006017124A2
(en)
*
|
2004-07-09 |
2006-02-16 |
Cengent Therapeutics, Inc. |
Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases
|
|
EP1773348A4
(de)
|
2004-07-12 |
2009-05-20 |
Idun Pharmaceuticals Inc |
Tetrapeptid-analoga
|
|
EP1841749A1
(de)
*
|
2004-09-02 |
2007-10-10 |
Metabasis Therapeutics, Inc. |
Thiazol- und thiadiazolderivate als inhibitoren von tyrosinphosphatasen
|
|
EP1802303B1
(de)
|
2004-09-17 |
2011-11-02 |
Whitehead Institute For Biomedical Research |
Verbindungen, zusammensetzungen und verfahren zur verhinderung einer a-synuklein-vergiftung
|
|
WO2006066074A2
(en)
|
2004-12-16 |
2006-06-22 |
The Regents Of The University Of California |
Lung-targeted drugs
|
|
WO2006068978A2
(en)
|
2004-12-21 |
2006-06-29 |
Takeda Pharmaceutial Company Limited |
Dipeptidyl peptidase inhibitors
|
|
EP1866319B1
(de)
|
2005-04-01 |
2011-11-23 |
The Regents of The University of California |
Phosphono-pent-2-en-1-yl-nukleoside und analoga
|
|
US20090156545A1
(en)
*
|
2005-04-01 |
2009-06-18 |
Hostetler Karl Y |
Substituted Phosphate Esters of Nucleoside Phosphonates
|
|
JP5336180B2
(ja)
|
2005-05-23 |
2013-11-06 |
ナチュラル オータナティブス インターナショナル |
β−アラニンの徐放のための組成物及び方法
|
|
CA2598216C
(en)
*
|
2005-06-17 |
2014-04-08 |
Ligand Pharmaceuticals Incorporated |
Androgen receptor modulator compounds and methods
|
|
US20100098640A1
(en)
*
|
2005-06-20 |
2010-04-22 |
Cohen Seth M |
Multidentate Pyrone-Derived Chelators for Medicinal Imaging and Chelation
|
|
US20080058282A1
(en)
|
2005-08-30 |
2008-03-06 |
Fallon Joan M |
Use of lactulose in the treatment of autism
|
|
US8492428B2
(en)
*
|
2005-09-20 |
2013-07-23 |
Mayo Foundation For Medical Education And Research |
Small-molecule botulinum toxin inhibitors
|
|
US8119655B2
(en)
|
2005-10-07 |
2012-02-21 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
|
WO2007076160A2
(en)
*
|
2005-12-28 |
2007-07-05 |
Acidophil Llc |
C-10 carbamates of taxanes
|
|
MX2008011842A
(es)
*
|
2006-03-13 |
2008-10-02 |
Encysive Pharmaceuticals Inc |
Procedimientos y composiciones para el tratamiento de insuficiencia cardiaca diastolica.
|
|
AU2007225088B2
(en)
|
2006-03-13 |
2012-09-13 |
Kyorin Pharmaceutical Co., Ltd |
Aminoquinolones as GSK-3 inhibitors
|
|
MX2008011844A
(es)
*
|
2006-03-13 |
2008-10-02 |
Encysive Pharmaceuticals Inc |
Formulaciones de sitaxsentano de sodio.
|
|
CA2647543A1
(en)
*
|
2006-03-29 |
2007-11-08 |
Foldrx Pharmaceuticals, Inc. |
Inhibition of alpha-synuclein toxicity
|
|
US20080026061A1
(en)
*
|
2006-06-22 |
2008-01-31 |
Reichwein John F |
Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
|
|
ES2439994T3
(es)
|
2006-08-28 |
2014-01-27 |
Kyowa Hakko Kirin Co., Ltd. |
Anticuerpos antagonistas monoclonales humanos específicos de LIGHT humano
|
|
PL2066662T3
(pl)
|
2006-09-21 |
2013-05-31 |
Kyorin Seiyaku Kk |
Inhibitory hydrolaz serynowych
|
|
AU2007313961A1
(en)
|
2006-10-09 |
2008-05-08 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
|
EP2223925A1
(de)
|
2006-10-09 |
2010-09-01 |
Takeda Pharmaceutical Company Limited |
Kinase-Inhibitoren
|
|
EP2617423A1
(de)
|
2006-10-19 |
2013-07-24 |
Genzyme Corporation |
Purinderivate zur Behandlung zystischer Erkrankungen
|
|
JP2010507585A
(ja)
|
2006-10-19 |
2010-03-11 |
オースペックス・ファーマシューティカルズ・インコーポレイテッド |
置換インドール
|
|
EP2089359A2
(de)
|
2006-10-31 |
2009-08-19 |
Takeda Pharmaceutical Company Limited |
Inhibitoren von mapk-erk-kinase
|
|
WO2008057604A2
(en)
*
|
2006-11-08 |
2008-05-15 |
The Regents Of The University Of California |
Small molecule therapeutics, syntheses of analogues and derivatives and methods of use
|
|
CA2671766A1
(en)
*
|
2006-12-22 |
2008-07-03 |
Encysive Pharmaceuticals, Inc. |
Modulators of c3a receptor and methods of use thereof
|
|
WO2008106167A1
(en)
*
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
|
|
PT2144604E
(pt)
*
|
2007-02-28 |
2011-10-19 |
Conatus Pharmaceuticals Inc |
Métodos para o tratamento da hepatite c viral crónica utilizando ro-113-0830
|
|
WO2008140859A1
(en)
|
2007-03-15 |
2008-11-20 |
Auspex Pharmaceuticals, Inc. |
Deuterated venlafaxines and 0-desmetylvenlafaxines with serotoninergic and / or norepinephrinergic activity
|
|
EP2170062A4
(de)
*
|
2007-07-12 |
2010-12-29 |
Tragara Pharmaceuticals Inc |
Verfahren und zusammensetzungen zur behandlung von krebserkrankungen, tumoren und tumorvermittelten erkrankungen
|
|
WO2009035634A2
(en)
*
|
2007-09-11 |
2009-03-19 |
Activx Biosciences, Inc. |
Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
|
|
CN102344457B
(zh)
|
2007-09-12 |
2015-07-22 |
杏林制药株式会社 |
作为 gsk-3 抑制剂的螺环状氨基喹诺酮
|
|
WO2009042711A1
(en)
|
2007-09-25 |
2009-04-02 |
Takeda Pharmaceutical Company Limited |
Polo-like kinase inhibitors
|
|
US20090264421A1
(en)
*
|
2007-10-05 |
2009-10-22 |
Bible Keith C |
Methods and Compositions for Treating Cancer
|
|
CA2696807C
(en)
|
2007-11-08 |
2017-11-28 |
Ambit Biosciences Corp. |
Methods of administering n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease
|
|
JP2011504485A
(ja)
*
|
2007-11-21 |
2011-02-10 |
ファーマクシス リミテッド |
Ｓｓａｏ／ｖａｐ−１のハロアリルアミン阻害剤およびその用途
|
|
KR101595238B1
(ko)
|
2007-12-21 |
2016-02-18 |
리간드 파마슈티칼스 인코포레이티드 |
선택적 안드로겐 수용체 조절제(ｓａｒｍ) 및 이의 용도
|
|
US8658163B2
(en)
|
2008-03-13 |
2014-02-25 |
Curemark Llc |
Compositions and use thereof for treating symptoms of preeclampsia
|
|
SI2947072T1
(sl)
|
2008-03-17 |
2017-03-31 |
Ambit Biosciences Corporation |
1-(3-(6,7-dimetoksikinazolin-4-iloksi)fenil)-3-(5-1,1,1-trifluoro-2- metilpropan-2-il)izoksazol-3-il)urea kot modulator raf kinaze pri zdravljenju rakavih bolezni
|
|
TW200946541A
(en)
*
|
2008-03-27 |
2009-11-16 |
Idenix Pharmaceuticals Inc |
Solid forms of an anti-HIV phosphoindole compound
|
|
US8084025B2
(en)
|
2008-04-18 |
2011-12-27 |
Curemark Llc |
Method for the treatment of the symptoms of drug and alcohol addiction
|
|
BRPI0912842A8
(pt)
*
|
2008-05-20 |
2019-01-29 |
Cerenis Therapeutics Holding |
composição farmacêutica, métodos para prevenir ou tratar o rubor induzido por niacina em um indivíduo, para reduzir pelo menos um sintoma de rubor relacionado com a terapia com niacina em um indivíduo, para diminuir os efeitos colaterais relacionados com a protaglandina em um indivíduo, para diminuir uma taxa de descontinuação do tratamento com niacina por um indivíduo, para aumentar a submissão do paciente ao tratamento com niacina, para tratar aterosclerose em um paciente, para tratar uma doença relacionada com um perfil de hdl baixo em um paciente, formulação do ácido nicotínico de dispensação modificada, uso da composição farmacêutica, e, microcápsula de aspirina
|
|
WO2010008847A2
(en)
|
2008-06-24 |
2010-01-21 |
Takeda Pharmaceutical Company Limited |
Pi3k/m tor inhibitors
|
|
PL2318035T3
(pl)
|
2008-07-01 |
2019-10-31 |
Curemark Llc |
Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
|
|
CN102300989B
(zh)
|
2009-01-06 |
2015-12-09 |
柯尔朗恩有限责任公司 |
用于治疗或预防金黄色葡萄球菌感染以及用于根除或减少表面上金黄色葡萄球菌的组合物和方法
|
|
KR20170005191A
(ko)
|
2009-01-06 |
2017-01-11 |
큐어론 엘엘씨 |
이. 콜라이에 의한 구강 감염의 치료 또는 예방을 위한 조성물 및 방법
|
|
WO2010088450A2
(en)
|
2009-01-30 |
2010-08-05 |
Celladon Corporation |
Methods for treating diseases associated with the modulation of serca
|
|
US8568793B2
(en)
|
2009-02-11 |
2013-10-29 |
Hope Medical Enterprises, Inc. |
Sodium nitrite-containing pharmaceutical compositions
|
|
AR075633A1
(es)
|
2009-02-27 |
2011-04-20 |
Ambit Biosciences Corp |
Compuestos moduladores de jak quinasa y sus metodos de uso
|
|
EP2403860B1
(de)
|
2009-03-04 |
2015-11-04 |
IDENIX Pharmaceuticals, Inc. |
Phosphothiophene und phosphothiazole als hcv polymerase inhibitoren
|
|
MX2011009413A
(es)
|
2009-03-11 |
2011-10-21 |
Ambit Biosciences Corp |
Combinacion de una indazolilaminopirrolotriazina y taxano para tratamiento contra cancer.
|
|
CN102438588B
(zh)
|
2009-03-23 |
2015-04-01 |
埃姆比特生物科学公司 |
使用联合治疗法治疗疾病的方法
|
|
SG174527A1
(en)
|
2009-03-27 |
2011-11-28 |
Pathway Therapeutics Inc |
Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
|
WO2010110686A1
(en)
|
2009-03-27 |
2010-09-30 |
Pathway Therapeutics Limited |
Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
|
|
WO2010111626A2
(en)
|
2009-03-27 |
2010-09-30 |
Takeda Pharmaceutical Company Limited |
Poly (adp-ribose) polymerase (parp) inhibitors
|
|
US9056050B2
(en)
|
2009-04-13 |
2015-06-16 |
Curemark Llc |
Enzyme delivery systems and methods of preparation and use
|
|
KR101687144B1
(ko)
|
2009-04-22 |
2016-12-15 |
액시킨 파마수티컬스 인코포레이티드 |
2,5-이치환된 아릴설폰아마이드 ｃｃｒ3 길항제
|
|
EP2727908A3
(de)
|
2009-04-22 |
2014-08-20 |
Axikin Pharmaceuticals, Inc. |
2,5-disubstituierte Arylsulfonamid-CCR3-Antagonisten
|
|
RU2539591C2
(ru)
|
2009-04-22 |
2015-01-20 |
Аксикин Фармасьютикалз, Инк. |
Антагонисты арилсульфонамида ccr3
|
|
SMT202000092T1
(it)
|
2009-05-14 |
2020-05-08 |
Ambit Biosciences Corp |
Formulazione essiccata a spruzzo o liofilizzata di ac220
|
|
US8486939B2
(en)
|
2009-07-07 |
2013-07-16 |
Pathway Therapeutics Inc. |
Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
|
|
AU2010270605B2
(en)
|
2009-07-08 |
2014-07-31 |
Hope Medical Enterprises, Inc. Dba Hope Pharmaceuticals |
Sodium thiosulfate-containing pharmaceutical compositions
|
|
US8404728B2
(en)
|
2009-07-30 |
2013-03-26 |
Mayo Foundation For Medical Education And Research |
Small-molecule botulinum toxin inhibitors
|
|
EP2459561A1
(de)
|
2009-07-30 |
2012-06-06 |
Takeda Pharmaceutical Company Limited |
Poly(adp-ribose)-polymerase (parp)-hemmer
|
|
EP2461811B1
(de)
|
2009-08-05 |
2016-04-20 |
Idenix Pharmaceuticals LLC. |
Makrocyclische serinproteasehemmer gegen virale infektionen, im besonderen hvc
|
|
AU2010282399A1
(en)
*
|
2009-08-14 |
2012-03-01 |
Cerenis Therapeutics Holding S.A. |
Use of PPAR delta ligands for the treatment or prevention of inflammation or energy metabolism/production related diseases
|
|
WO2011041293A1
(en)
|
2009-09-30 |
2011-04-07 |
Takeda Pharmaceutical Company Limited |
Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
|
|
TW201120037A
(en)
|
2009-10-26 |
2011-06-16 |
Sunesis Pharmaceuticals Inc |
Compounds and methods for treatment of cancer
|
|
WO2011056764A1
(en)
|
2009-11-05 |
2011-05-12 |
Ambit Biosciences Corp. |
Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
|
|
WO2011057214A2
(en)
|
2009-11-09 |
2011-05-12 |
Neurogenetic Pharmaceuticals, Inc. |
Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
|
|
US20110301235A1
(en)
|
2009-12-02 |
2011-12-08 |
Alquest Therapeutics, Inc. |
Organoselenium compounds and uses thereof
|
|
KR20120118008A
(ko)
|
2009-12-18 |
2012-10-25 |
아이데닉스 파마슈티칼스, 인코포레이티드 |
5,5-융합 아릴렌 또는 헤테로아릴렌 간염 ｃ 바이러스 억제제
|
|
IN2012DN04858A
(de)
*
|
2009-12-23 |
2015-09-25 |
Map Pharmaceuticals Inc |
|
|
CN103664873B
(zh)
*
|
2009-12-30 |
2016-06-15 |
深圳信立泰药业股份有限公司 |
作为二肽基肽酶iv(dpp-iv)抑制剂的3-(3-氨基哌啶-1-基)-5-氧代-1,2,4-三嗪衍生物
|
|
PL2531501T3
(pl)
|
2010-02-03 |
2014-05-30 |
Takeda Pharmaceuticals Co |
Inhibitory kinazy 1 regulującej sygnał apoptotyczny
|
|
AU2011223873B2
(en)
|
2010-03-02 |
2015-06-25 |
Axikin Pharmaceuticals, Inc. |
Isotopically enriched arylsulfonamide CCR3 antagonists
|
|
WO2011112689A2
(en)
|
2010-03-11 |
2011-09-15 |
Ambit Biosciences Corp. |
Saltz of an indazolylpyrrolotriazine
|
|
EP2547655B1
(de)
|
2010-03-17 |
2016-03-09 |
Axikin Pharmaceuticals, Inc. |
Arylsulfonamid-ccr-3-antagonisten
|
|
MX341050B
(es)
|
2010-04-07 |
2016-08-05 |
Celgene Corp * |
Metodos para tratar infeccion viral respiratoria.
|
|
MX2012013879A
(es)
|
2010-06-01 |
2013-04-03 |
Biotheryx Inc |
Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas.
|
|
JP6019015B2
(ja)
|
2010-06-01 |
2016-11-02 |
ビオトヘルイク， インコーポレイテッド |
６−シクロヘキシル−１−ヒドロキシ−４−メチル−２（１ｈ）−ピリドンを使用する血液悪性疾患の治療方法
|
|
MX2012014273A
(es)
|
2010-06-07 |
2013-03-22 |
Novomedix Llc |
Compuestos furanilo y su uso.
|
|
JP6069661B2
(ja)
|
2010-06-24 |
2017-02-01 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
種々のアミロイドβペプチドアロフォームレベルの調節における組成物及びその使用
|
|
US20130178522A1
(en)
|
2010-07-19 |
2013-07-11 |
James M. Jamison |
Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
|
|
EP2611448A1
(de)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
7-cyclylchinazolinderivate und verwendungsverfahren dafür
|
|
WO2012030948A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Quinazoline compounds and methods of use thereof
|
|
US20130317045A1
(en)
|
2010-09-01 |
2013-11-28 |
Ambit Biosciences Corporation |
Thienopyridine and thienopyrimidine compounds and methods of use thereof
|
|
WO2012030918A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Adenosine a3 receptor modulating compounds and methods of use thereof
|
|
ES2579942T3
(es)
|
2010-09-01 |
2016-08-17 |
Ambit Biosciences Corporation |
Pirazolilaminoquinazolina ópticamente activa y composiciones farmacéuticas y métodos de uso de la misma
|
|
WO2012030924A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Azolopyridine and azolopyrimidine compounds and methods of use thereof
|
|
EP2611794A1
(de)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
4--azolylaminochinazolinderivate und verwendungsverfahren dafür
|
|
US20130296363A1
(en)
|
2010-09-01 |
2013-11-07 |
Ambit Biosciences Corporation |
Quinoline and isoquinoline derivatives for use as jak modulators
|
|
CN103270030B
(zh)
|
2010-09-01 |
2016-01-20 |
埃姆比特生物科学公司 |
吡唑基氨基喹唑啉的氢溴酸盐
|
|
EP2611793A1
(de)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
2-cyclochinazolinderivate und verwendungsverfahren dafür
|
|
US8859502B2
(en)
|
2010-09-13 |
2014-10-14 |
Celgene Corporation |
Therapy for MLL-rearranged leukemia
|
|
WO2012044641A1
(en)
|
2010-09-29 |
2012-04-05 |
Pathway Therapeutics Inc. |
1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
|
CN103298786B
(zh)
|
2010-10-11 |
2016-01-20 |
埃克希金医药品有限公司 |
芳基磺酰胺盐ccr3拮抗剂
|
|
WO2012080050A1
(en)
|
2010-12-14 |
2012-06-21 |
F. Hoffmann-La Roche Ag |
Solid forms of a phenoxybenzenesulfonyl compound
|
|
AR085352A1
(es)
|
2011-02-10 |
2013-09-25 |
Idenix Pharmaceuticals Inc |
Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
|
|
JP2014509648A
(ja)
|
2011-03-28 |
2014-04-21 |
メイ プハルマ，インコーポレーテッド |
（α−置換シクロアルキルアミノ及びヘテロシクリルアミノ）ピリミジニル及び１，３，５−トリアジニルベンズイミダゾール、その医薬組成物、並びに増殖性疾患の治療におけるそれらの使用
|
|
ES2608967T3
(es)
|
2011-03-28 |
2017-04-17 |
Mei Pharma, Inc. |
(Aralquilamino sustituido en alfa y heteroarilalquilamino)pirimidinil y 1,3,5-triazinil benzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para usar en el tratamiento de enfermedades proliferativas
|
|
WO2012135166A1
(en)
|
2011-03-28 |
2012-10-04 |
Pathway Therapeutics Inc. |
(fused ring arylamino and heterocyclylamino) pyrimidynyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
|
US8980252B2
(en)
|
2011-04-21 |
2015-03-17 |
Curemark Llc |
Methods of treatment of schizophrenia
|
|
MX2013015373A
(es)
|
2011-06-23 |
2014-02-11 |
Map Pharmaceuticals Inc |
Nuevos analogos de fluoroergolina.
|
|
WO2013022872A1
(en)
|
2011-08-10 |
2013-02-14 |
Celgene Corporation |
Gene methylation biomarkers and methods of use thereof
|
|
CN103906837A
(zh)
|
2011-09-02 |
2014-07-02 |
辛达克斯制药股份有限公司 |
治疗乳腺癌的方法
|
|
WO2013037482A1
(en)
|
2011-09-15 |
2013-03-21 |
Phenex Pharmaceuticals Ag |
Farnesoid x receptor agonists for cancer treatment and prevention
|
|
CA2849708A1
(en)
|
2011-09-23 |
2013-03-28 |
Celgene Corporation |
Romidepsin and 5 - azacitidine for use in treating lymphoma
|
|
US20130244950A1
(en)
|
2011-09-26 |
2013-09-19 |
Celgene Corporation |
Combination therapy for chemoresistant cancers
|
|
US9125884B2
(en)
|
2011-11-01 |
2015-09-08 |
Celgene Corporation |
Methods for treating cancers using oral formulations of cytidine analogs
|
|
WO2013085902A1
(en)
|
2011-12-05 |
2013-06-13 |
The University Of Texas M.D. |
Combination therapy methods for treating an inflammatory breast cancer
|
|
SG11201403434YA
(en)
|
2011-12-19 |
2014-09-26 |
Map Pharmaceuticals Inc |
Novel iso-ergoline derivatives
|
|
CA2859175A1
(en)
|
2011-12-21 |
2013-06-27 |
Map Pharmaceuticals, Inc. |
Novel neuromodulatory compounds
|
|
WO2013130600A1
(en)
|
2012-02-29 |
2013-09-06 |
Ambit Biosciences Corporation |
Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
|
|
WO2013134047A2
(en)
|
2012-03-07 |
2013-09-12 |
The Mclean Hospital Corporation |
Aminoquinoline derivatives and uses thereof
|
|
KR20140138293A
(ko)
|
2012-03-16 |
2014-12-03 |
액시킨 파마수티컬스 인코포레이티드 |
3,5-다이아미노피라졸 키나아제 억제제
|
|
WO2013148919A1
(en)
|
2012-03-30 |
2013-10-03 |
The Regents Of The University Of Colorado, A Body Corporate |
Treatment of multiple myeloma
|
|
EP3438087A1
(de)
|
2012-05-02 |
2019-02-06 |
Boehringer Ingelheim International GmbH |
Substituierte 3-haloallylamininhibitoren von ssao und verwendungen davon
|
|
US10350278B2
(en)
|
2012-05-30 |
2019-07-16 |
Curemark, Llc |
Methods of treating Celiac disease
|
|
EP3406598B1
(de)
|
2012-06-14 |
2020-01-29 |
Mayo Foundation for Medical Education and Research |
Pyrazolderivate als hemmer von stat3
|
|
US9012640B2
(en)
|
2012-06-22 |
2015-04-21 |
Map Pharmaceuticals, Inc. |
Cabergoline derivatives
|
|
US8551535B1
(en)
|
2012-08-06 |
2013-10-08 |
Sarah McCann |
Homeopathic remedies and methods for enhancing weight loss
|
|
US9074186B2
(en)
|
2012-08-15 |
2015-07-07 |
Boston Medical Center Corporation |
Production of red blood cells and platelets from stem cells
|
|
AU2013202506B2
(en)
|
2012-09-07 |
2015-06-18 |
Celgene Corporation |
Resistance biomarkers for hdac inhibitors
|
|
CN104781240A
(zh)
|
2012-09-07 |
2015-07-15 |
埃克希金医药品有限公司 |
同位素富集的芳基磺酰胺ccr3拮抗剂
|
|
WO2014055647A1
(en)
|
2012-10-03 |
2014-04-10 |
Mei Pharma, Inc. |
(sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
|
|
WO2014074765A2
(en)
|
2012-11-08 |
2014-05-15 |
Summa Health System |
Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
|
|
AU2013202507B9
(en)
|
2012-11-14 |
2015-08-13 |
Celgene Corporation |
Inhibition of drug resistant cancer cells
|
|
CN104955801B
(zh)
|
2012-11-30 |
2017-10-31 |
诺沃梅迪科斯有限公司 |
取代的二芳基磺酰胺及其用途
|
|
US9169214B2
(en)
|
2012-12-21 |
2015-10-27 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
|
|
BR112015014964A2
(pt)
|
2012-12-21 |
2017-07-11 |
Map Pharmaceuticals Inc |
novos derivados de metisergida
|
|
CA2897665A1
(en)
|
2013-01-11 |
2014-07-17 |
Mayo Foundation For Medical Education And Research |
Vitamins c and k for treating polycystic diseases
|
|
CA2902232C
(en)
|
2013-02-22 |
2020-12-29 |
University Of Southern California |
Methods for treatment of ophthalmic diseases and disorders
|
|
EP2968296B1
(de)
|
2013-03-12 |
2020-09-02 |
The Regents of the University of California |
Gammasekretasemodulatoren
|
|
KR102230461B1
(ko)
|
2013-03-15 |
2021-03-22 |
유니버시티 오브 써던 캘리포니아 |
엔지오텐신-관련 질환들의 치료를 위한 방법들, 화합물들 및 조성물들
|
|
EA201892769A3
(ru)
|
2013-03-15 |
2019-08-30 |
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния |
Сложные диэфиры ациклических нуклеозидфосфонатов
|
|
US9968627B2
(en)
|
2013-03-26 |
2018-05-15 |
Celgene Corporation |
Solid forms comprising 4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one and a coformer, compositions and methods of use thereof
|
|
SG11201509982UA
(de)
|
2013-06-06 |
2016-04-28 |
Igenica Biotherapeutics Inc |
|
|
EP2815749A1
(de)
|
2013-06-20 |
2014-12-24 |
IP Gesellschaft für Management mbH |
Feste Form von 4-Amino-2-(2,6-dioxopiperidin-3-yl)isoindolin-1,3-dion mit spezifischem Röntgenbeugungsspektrum
|
|
NZ631142A
(en)
|
2013-09-18 |
2016-03-31 |
Axikin Pharmaceuticals Inc |
Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
|
|
EP3046924A1
(de)
|
2013-09-20 |
2016-07-27 |
IDENIX Pharmaceuticals, Inc. |
Inhibitoren des hepatitis-c-virus
|
|
US9700549B2
(en)
|
2013-10-03 |
2017-07-11 |
David Wise |
Compositions and methods for treating pelvic pain and other conditions
|
|
US9714232B2
(en)
|
2013-12-20 |
2017-07-25 |
Sunshine Lake Pharma Co., Ltd. |
Substituted piperazine compounds and methods of use thereof
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
US20170066779A1
(en)
|
2014-03-05 |
2017-03-09 |
Idenix Pharmaceuticals Llc |
Solid forms of a flaviviridae virus inhibitor compound and salts thereof
|
|
KR102416358B1
(ko)
|
2014-03-20 |
2022-07-07 |
카펠라 테라퓨틱스, 인크. |
암 치료용의 ｅｒｂｂ 티로신 키나제 억제제로서의 벤즈이미다졸 유도체
|
|
KR102409739B1
(ko)
|
2014-03-20 |
2022-06-17 |
카펠라 테라퓨틱스, 인크. |
암 치료용의 ｅｒｂｂ 티로신 키나제 억제제로서의 벤즈이미다졸 유도체
|
|
MX2016012574A
(es)
|
2014-03-28 |
2017-09-26 |
Calitor Sciences Llc |
Compuestos heteroarilo sustituidos y metodos de uso.
|
|
ES2751652T3
(es)
|
2014-05-12 |
2020-04-01 |
Conatus Pharmaceuticals Inc |
Tratamiento con inhibidor de caspasa emricasan de las complicaciones por las enfermedades hepáticas crónicas
|
|
WO2015195634A1
(en)
|
2014-06-17 |
2015-12-23 |
Celgne Corporation |
Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
|
|
WO2015195786A2
(en)
|
2014-06-17 |
2015-12-23 |
Celgene Corporation |
Methods for treating cancers using oral formulations of cytidine analogs
|
|
US9527815B2
(en)
|
2014-06-18 |
2016-12-27 |
Biotheryx, Inc. |
Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
|
|
US9499514B2
(en)
|
2014-07-11 |
2016-11-22 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
|
US20160045609A1
(en)
|
2014-08-14 |
2016-02-18 |
Mamoun M. Alhamadsheh |
Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
|
|
BR112017005111B1
(pt)
|
2014-09-15 |
2023-02-14 |
The Regents Of The University Of California |
Compostos análogos de nucleotídeo acíclico, composição farmacêutica contendo tais compostos, e usos da composição no tratamento de uma infecção por papilomavírus
|
|
WO2016065264A1
(en)
|
2014-10-24 |
2016-04-28 |
Biogen Ma Inc. |
Diterpenoid derivatives and methods of use thereof
|
|
US10472346B2
(en)
|
2014-10-31 |
2019-11-12 |
The General Hospital Corporation |
Potent gamma-secretase modulators
|
|
PL3333191T3
(pl)
|
2014-12-11 |
2021-05-04 |
Pierre Fabre Médicament |
Przeciwciała przeciwko c10orf54 i ich zastosowania
|
|
US9546163B2
(en)
|
2014-12-23 |
2017-01-17 |
Axikin Pharmaceuticals, Inc. |
3,5-diaminopyrazole kinase inhibitors
|
|
JP2018502889A
(ja)
|
2015-01-20 |
2018-02-01 |
エックスオーシー ファーマシューティカルズ インコーポレイテッドＸｏｃ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ |
イソエルゴリン化合物およびその使用
|
|
JP6856532B2
(ja)
|
2015-01-20 |
2021-04-07 |
エックスオーシー ファーマシューティカルズ インコーポレイテッドＸｏｃ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ |
エルゴリン化合物およびその使用
|
|
MX2017011194A
(es)
|
2015-03-03 |
2018-04-10 |
Kymab Ltd |
Anticuerpos, usos y métodos.
|
|
JP2018508593A
(ja)
|
2015-03-20 |
2018-03-29 |
シンダックス ファーマシューティカルズ，インコーポレイティド |
がんを処置するためのｈｄａｃ阻害剤および抗ｐｄ−１抗体の組合せ
|
|
WO2016176617A2
(en)
|
2015-04-29 |
2016-11-03 |
New York University |
Method for treating high-grade gliomas
|
|
EA036837B1
(ru)
|
2015-06-23 |
2020-12-25 |
Нейрокрин Байосайенсиз, Инк. |
Ингибиторы vmat2 для лечения неврологических заболеваний или расстройств
|
|
HUE044698T2
(hu)
|
2015-08-17 |
2019-11-28 |
Kura Oncology Inc |
Kezelési módszer rákos páciensek kezelésére farnezil-transzferáz inhibitorokkal
|
|
AU2016318136B2
(en)
|
2015-09-02 |
2022-10-20 |
Syndax Pharmaceuticals, Inc. |
Selection of patients for combination therapy
|
|
WO2017044434A1
(en)
|
2015-09-11 |
2017-03-16 |
Sunshine Lake Pharma Co., Ltd. |
Substituted heteroaryl compounds and methods of use
|
|
EP3353214B1
(de)
|
2015-09-25 |
2021-08-18 |
Universität Duisburg-Essen |
Wirkstoffe zur hemmung von kallikrein-8 zur verwendung bei der vorbeugung und behandlung von morbus alzheimer
|
|
MY193767A
(en)
|
2015-10-30 |
2022-10-27 |
Neurocrine Biosciences Inc |
Valbenazine salts and polymorphs thereof
|
|
WO2017079566A1
(en)
|
2015-11-05 |
2017-05-11 |
Conatus Pharmaceuticals, Inc. |
Caspase inhibitors for use in the treatment of liver cancer
|
|
US10112924B2
(en)
|
2015-12-02 |
2018-10-30 |
Astraea Therapeutics, Inc. |
Piperdinyl nociceptin receptor compounds
|
|
JP7011596B2
(ja)
|
2015-12-02 |
2022-02-10 |
アストライア セラピューティクス， エルエルシー |
ピペリジニルノシセプチン受容体化合物
|
|
CN108925135B
(zh)
|
2015-12-23 |
2025-09-19 |
纽罗克里生物科学有限公司 |
制备(S)-(2R,3R,11bR)-3-异丁基-9,10-二甲氧基-2,3,4,6,7,11b-六氢-1H-吡啶并[2,1-a]异喹啉-2-基2-氨基-3-甲基丁酸酯二(4-甲基苯磺酸盐)的合成方法
|
|
JP2019500397A
(ja)
|
2015-12-31 |
2019-01-10 |
クオナトウス ファーマシューティカルズ，インコーポレイテッド |
カスパーゼ阻害剤を肝疾患の治療に使用する方法
|
|
CN108430473B
(zh)
|
2016-01-08 |
2021-08-31 |
细胞基因公司 |
抗增殖化合物以及其药物组合物和用途
|
|
US10960013B2
(en)
|
2016-03-04 |
2021-03-30 |
East Carolina University |
J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
|
|
EP3426301A4
(de)
|
2016-03-08 |
2019-11-06 |
Los Gatos Pharmaceuticals, Inc. |
Verbundnanopartikel und verwendungen davon
|
|
US10407437B2
(en)
|
2016-03-08 |
2019-09-10 |
Los Gatos Pharmaceuticals, Inc. |
Camptothecin derivatives and uses thereof
|
|
WO2017180589A1
(en)
|
2016-04-11 |
2017-10-19 |
Auspex Pharmaceuticals, Inc. |
Deuterated ketamine derivatives
|
|
WO2017180794A1
(en)
|
2016-04-13 |
2017-10-19 |
Skyline Antiinfectives, Inc. |
Deuterated o-sulfated beta-lactam hydroxamic acids and deuterated n-sulfated beta-lactams
|
|
WO2017184968A1
(en)
|
2016-04-22 |
2017-10-26 |
Kura Oncology, Inc. |
Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
|
|
ES2939373T3
(es)
|
2016-05-13 |
2023-04-21 |
Pasteur Institut |
Inhibición de los receptores de acetilcolina nicotínicos beta-2 para tratar la patología de la enfermedad de Alzheimer
|
|
TWI753910B
(zh)
|
2016-05-16 |
2022-02-01 |
美商拜歐斯瑞克斯公司 |
吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
|
|
WO2018013693A1
(en)
|
2016-07-13 |
2018-01-18 |
Celgene Corporation |
Solid dispersions and cocrystals comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione compositions and methods of use thereof
|
|
WO2018013689A1
(en)
|
2016-07-13 |
2018-01-18 |
Celgene Corporation |
Solid dispersions and solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, method of preparation and use thereof
|
|
US10919904B2
(en)
|
2016-08-17 |
2021-02-16 |
North Carolina State University |
Northern-southern route to synthesis of bacteriochlorins
|
|
CN109982687A
(zh)
|
2016-09-19 |
2019-07-05 |
梅制药公司 |
联合疗法
|
|
EP3534947A1
(de)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antikörper, kombinationen mit antikörpern, biomarker, verwendungen und verfahren
|
|
JP2019534290A
(ja)
|
2016-11-03 |
2019-11-28 |
クラ オンコロジー， インコーポレイテッド |
癌の治療方法において使用するためのファルネシルトランスフェラーゼ阻害剤
|
|
TW201828932A
(zh)
|
2016-11-09 |
2018-08-16 |
美商諾沃麥迪斯有限責任公司 |
1,1-二甲基雙胍之亞硝酸鹽、醫藥組合物及使用方法
|
|
WO2018089692A1
(en)
|
2016-11-09 |
2018-05-17 |
Phloronol, Inc. |
Eckol derivatives, methods of synthesis and uses thereof
|
|
WO2018102252A1
(en)
|
2016-11-30 |
2018-06-07 |
North Carolina State University |
Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
|
|
EP3548007A4
(de)
|
2016-12-01 |
2020-08-12 |
Ignyta, Inc. |
Verfahren zur behandlung von krebs
|
|
TW202345829A
(zh)
|
2016-12-02 |
2023-12-01 |
美商紐羅克里生物科學有限公司 |
戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
|
|
WO2018140092A1
(en)
|
2017-01-27 |
2018-08-02 |
Obrien Christopher F |
Methods for the administration of certain vmat2 inhibitors
|
|
EP3576755A4
(de)
|
2017-02-02 |
2020-12-02 |
McMaster University |
Bikarbonat als potenziator für antimikrobielle wirkstoffe
|
|
KR102874295B1
(ko)
|
2017-02-17 |
2025-10-20 |
에이도스 테라퓨틱스, 인코포레이티드 |
Ag-10, 이의 중간체, 및 이의 염을 제조하는 방법
|
|
EP4119142A1
(de)
|
2017-02-21 |
2023-01-18 |
Kura Oncology, Inc. |
Verfahren zur behandlung von krebs mit farnesyltransferase-inhibitoren
|
|
US9956215B1
(en)
|
2017-02-21 |
2018-05-01 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
WO2018164996A1
(en)
|
2017-03-06 |
2018-09-13 |
Neurocrine Biosciences, Inc. |
Dosing regimen for valbenazine
|
|
CN110709386B
(zh)
|
2017-03-30 |
2022-06-07 |
凯瑞康宁生物工程（武汉）有限公司 |
双环杂芳基衍生物及其制备与用途
|
|
AU2018250823A1
(en)
|
2017-04-10 |
2019-10-17 |
Curemark, Llc |
Compositions for treating addiction
|
|
US11583570B2
(en)
|
2017-04-24 |
2023-02-21 |
Tsinghua University |
Use of autoinducer-related pathway in inducing apoptosis and anti-infective therapy
|
|
WO2018200605A1
(en)
|
2017-04-26 |
2018-11-01 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating levodopa-induced dyskinesia
|
|
JOP20190219A1
(ar)
|
2017-05-09 |
2019-09-22 |
Cardix Therapeutics LLC |
تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
|
|
US10085999B1
(en)
|
2017-05-10 |
2018-10-02 |
Arixa Pharmaceuticals, Inc. |
Beta-lactamase inhibitors and uses thereof
|
|
EP3630758A1
(de)
|
2017-06-01 |
2020-04-08 |
Xoc Pharmaceuticals, Inc |
Ergolinderivate zur verwendung in der medizin
|
|
JP2020525459A
(ja)
|
2017-06-26 |
2020-08-27 |
アンスティテュ・パストゥール |
Ｈｉｖリザーバーを排除し、ウイルス負荷を低減する処置
|
|
US10806730B2
(en)
|
2017-08-07 |
2020-10-20 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
MY200746A
(en)
|
2017-08-07 |
2024-01-13 |
Kura Oncology Inc |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
CN115109116A
(zh)
|
2017-08-17 |
2022-09-27 |
凯瑞康宁生物工程（武汉）有限公司 |
活性氧清除剂衍生物的制备及用途
|
|
AU2018324070B2
(en)
|
2017-09-01 |
2023-05-18 |
East Carolina University |
Compounds, compositions, kits, and methods for activating immune cells and/or an immune system response
|
|
WO2019041361A1
(en)
|
2017-09-04 |
2019-03-07 |
Xw Laboratories, Inc. |
PREPARATION AND USE OF A REACTIVE OXYGEN SPECIES TRAPPER
|
|
ES3024958T3
(en)
|
2017-09-21 |
2025-06-05 |
Neurocrine Biosciences Inc |
High dosage valbenazine formulation and compositions, methods, and kits related thereto
|
|
WO2019071021A2
(en)
|
2017-10-04 |
2019-04-11 |
The Regents Of The University Of California |
IMMUNOMODULATORY OLIGOSACCHARIDES
|
|
JP2021502959A
(ja)
|
2017-10-10 |
2021-02-04 |
ニューロクライン バイオサイエンシーズ，インコーポレイテッド |
特定のｖｍａｔ２インヒビターを投与するための方法
|
|
KR20250070134A
(ko)
|
2017-10-10 |
2025-05-20 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
특정 vmat2 억제제의 투여 방법
|
|
US20190216751A1
(en)
|
2017-11-15 |
2019-07-18 |
California State University Northridge |
Compositions and Methods for the Treatment and Prevention of Cancer
|
|
US10683297B2
(en)
|
2017-11-19 |
2020-06-16 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
|
WO2019113269A1
(en)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
|
WO2019139871A1
(en)
|
2018-01-10 |
2019-07-18 |
Cura Therapeutics Llc |
Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
|
|
JP7395480B2
(ja)
|
2018-01-10 |
2023-12-11 |
クラ セラピューティクス， エルエルシー |
フェニルスルホンアミドを含む薬学的組成物、及びそれらの治療的適用
|
|
IL275968B2
(en)
|
2018-01-10 |
2024-07-01 |
Xwpharma Ltd |
Prodrugs of ketamine, compositions and uses thereof
|
|
US11058668B2
(en)
|
2018-03-23 |
2021-07-13 |
Eidos Therapeutics, Inc. |
Methods of treating TTR amyloidosis using AG10
|
|
EP4438124A3
(de)
|
2018-04-27 |
2024-12-18 |
Spruce Biosciences, Inc. |
Verfahren zur behandlung von hoden- und eierstock-nebennierentumoren
|
|
AU2019266231B2
(en)
|
2018-05-07 |
2025-08-21 |
Syndax Pharmaceuticals, Inc. |
Selection of patients for combination therapy
|
|
WO2019232724A1
(en)
|
2018-06-06 |
2019-12-12 |
Xw Laboratories, Inc. |
Compounds as nuclear transport modulators and uses thereof
|
|
MX2020013004A
(es)
|
2018-06-14 |
2021-02-17 |
Neurocrine Biosciences Inc |
Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos.
|
|
US11447497B2
(en)
|
2018-06-29 |
2022-09-20 |
Histogen, Inc. |
(S)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
|
|
KR102767692B1
(ko)
|
2018-07-20 |
2025-02-17 |
피에르 파브르 메디카먼트 |
Vista의 수용체
|
|
WO2020019247A1
(en)
|
2018-07-26 |
2020-01-30 |
Xw Laboratories, Inc. |
Compounds as neurokinin-1 receptor antagonists and uses thereof
|
|
EP3829640A4
(de)
|
2018-08-01 |
2022-05-25 |
McMaster University |
Verfahren zur hemmung von mikrobenwachstum
|
|
SG11202100303QA
(en)
|
2018-08-15 |
2021-02-25 |
Neurocrine Biosciences Inc |
Methods for the administration of certain vmat2 inhibitors
|
|
IL325404A
(en)
|
2018-08-17 |
2026-02-01 |
Eidos Therapeutics Inc |
Spice formulations containing 3-(3-(5,3-dimethyl-1h-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid
|
|
ES2947089T3
(es)
|
2018-09-30 |
2023-08-01 |
Xwpharma Ltd |
Compuestos como antagonistas del receptor histamínico 3 neuronal y usos de los mismos
|
|
TW202031259A
(zh)
|
2018-11-01 |
2020-09-01 |
美商庫拉腫瘤技術股份有限公司 |
以法尼基轉移酶(farnesyltransferase)抑制劑治療癌症之方法
|
|
JP7407461B2
(ja)
|
2018-12-19 |
2024-01-04 |
シャイ・セラピューティクス・エルエルシー |
がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリーと相互作用する化合物
|
|
WO2020128033A1
(en)
|
2018-12-20 |
2020-06-25 |
Institut Pasteur |
Cellular metabolism of hiv-1 reservoir seeding in cd4+ t cells
|
|
TW202038953A
(zh)
|
2018-12-21 |
2020-11-01 |
美商庫拉腫瘤技術股份有限公司 |
鱗狀細胞癌之治療
|
|
TWI839461B
(zh)
|
2019-02-06 |
2024-04-21 |
美商戴斯阿爾法股份有限公司 |
Il-17a調節物及其用途
|
|
WO2020180663A1
(en)
|
2019-03-01 |
2020-09-10 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
PL3935042T3
(pl)
|
2019-03-07 |
2024-11-04 |
Nobo Medicine Inc. |
Inhibitory kaspazy i sposoby ich zastosowania
|
|
WO2020190604A1
(en)
|
2019-03-15 |
2020-09-24 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
|
AU2020254492A1
(en)
|
2019-03-29 |
2021-11-11 |
Kura Oncology, Inc. |
Methods of treating Squamous Cell Carcinomas with farnesyltransferase inhibitors
|
|
WO2020205387A1
(en)
|
2019-04-01 |
2020-10-08 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
AU2020257397B2
(en)
|
2019-04-19 |
2026-02-26 |
Ligand Pharmaceuticals Inc. |
Crystalline forms and methods of producing crystalline forms of a compound
|
|
WO2020223583A1
(en)
|
2019-05-02 |
2020-11-05 |
Kura Oncology, Inc. |
Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
|
|
EP3959292B1
(de)
|
2019-05-20 |
2025-07-02 |
NIRvana Sciences Inc. |
Farbstoffe mit geringer emission, zusammensetzungen damit und verfahren zu ihrer herstellung und verwendung
|
|
US20220249707A1
(en)
|
2019-05-20 |
2022-08-11 |
Nirvana Sciences Inc. |
Narrow emission dyes, compositions comprising same, and methods for making and using same
|
|
EP3997068A1
(de)
|
2019-07-11 |
2022-05-18 |
Cura Therapeutics, LLC |
Sulfonverbindungen und pharmazeutische zusammensetzungen daraus sowie ihre therapeutischen anwendungen zur behandlung von neurodegenerativen erkrankungen
|
|
CA3146159A1
(en)
|
2019-07-11 |
2021-01-14 |
Cura Therapeutics, Llc |
Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
|
|
CN118903087A
(zh)
|
2019-07-26 |
2024-11-08 |
埃斯佩尔维塔治疗股份有限公司 |
可用于预防或治疗疾病的官能化的长链烃一元和二元羧酸
|
|
US10940141B1
(en)
|
2019-08-23 |
2021-03-09 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
|
IL291345B2
(en)
|
2019-09-16 |
2024-04-01 |
Dice Alpha Inc |
Il-17a modulators and uses thereof
|
|
US20230008367A1
(en)
|
2019-09-26 |
2023-01-12 |
Abionyx Pharma Sa |
Compounds useful for treating liver diseases
|
|
WO2021068188A1
(en)
|
2019-10-11 |
2021-04-15 |
Waterstone Pharmaceuticals(Wuhan) Co., Ltd. |
Ws-635 uses thereof in medicine
|
|
EP4055011A1
(de)
|
2019-11-05 |
2022-09-14 |
Dermira, Inc |
Mrgprx2-antagonisten und ihre anwendungen
|
|
CN114845709B
(zh)
|
2019-11-05 |
2024-10-01 |
德米拉公司 |
用于治疗炎性病症的mrgprx2拮抗剂
|
|
JP7645256B2
(ja)
|
2019-11-05 |
2025-03-13 |
デルミラ インコーポレイテッド |
ＭｒｇｐｒＸ２アンタゴニストおよびその使用
|
|
CN112851622B
(zh)
|
2019-11-28 |
2023-01-10 |
中国海洋大学 |
一种大环内酯布雷菲德菌素a酯类衍生物及应用
|
|
TW202136237A
(zh)
|
2020-01-06 |
2021-10-01 |
大陸商廣東東陽光藥業有限公司 |
RORγt抑制劑及其製備方法和用途
|
|
TW202136238A
(zh)
|
2020-01-06 |
2021-10-01 |
大陸商廣東東陽光藥業有限公司 |
RORγt抑制劑及其製備方法和用途
|
|
WO2021242970A1
(en)
|
2020-05-29 |
2021-12-02 |
Boulder Bioscience Llc |
Methods for improved endovascular thrombectomy using 3,3'-diindolylmethane
|
|
EP4168414A1
(de)
|
2020-06-18 |
2023-04-26 |
Shy Therapeutics LLC |
Substituierte thienopyrimidine zur interaktion mit der ras-superfamilie zur behandlung von krebs, entzündlichen erkrankungen, rasopathien und fibrotischen erkrankungen
|
|
WO2021262992A1
(en)
|
2020-06-24 |
2021-12-30 |
Neurobo Pharmaceuticals, Inc. |
Gemcabene for treatment of cytokine storms and viral-induced inflammation
|
|
JP7828905B2
(ja)
|
2020-06-30 |
2026-03-12 |
プロセッタ バイオサイエンシズ， インク． |
イソキノリン誘導体、合成の方法及びそれらの使用
|
|
CN113861185B
(zh)
|
2020-06-30 |
2023-04-07 |
广东东阳光药业有限公司 |
2-(取代的嘧啶基)噻唑甲酰胺化合物的盐及其组合物和用途
|
|
US20240317681A1
(en)
|
2020-07-07 |
2024-09-26 |
Sunshine Lake Pharma Co., Ltd. |
Pyrrolidine amide derivative salt and use thereof
|
|
US11541009B2
(en)
|
2020-09-10 |
2023-01-03 |
Curemark, Llc |
Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
|
|
WO2022061348A1
(en)
|
2020-09-16 |
2022-03-24 |
Biotheryx, Inc. |
Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
|
|
WO2022087335A1
(en)
|
2020-10-23 |
2022-04-28 |
Biotheryx, Inc. |
Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
|
|
TW202237580A
(zh)
|
2020-12-14 |
2022-10-01 |
美商拜歐斯瑞克斯公司 |
Pde4降解劑、醫藥組合物及治療應用
|
|
JP2024501640A
(ja)
|
2020-12-16 |
2024-01-15 |
インパクト バイオメディシンズ インコーポレイテッド |
フェドラチニブの投薬
|
|
EP4284377A1
(de)
|
2021-01-27 |
2023-12-06 |
Shy Therapeutics LLC |
Verfahren zur behandlung von fibrotischen erkrankungen
|
|
WO2022165000A1
(en)
|
2021-01-27 |
2022-08-04 |
Shy Therapeutics, Llc |
Methods for the treatment of fibrotic disease
|
|
WO2022189856A1
(en)
|
2021-03-08 |
2022-09-15 |
Abionyx Pharma Sa |
Compounds useful for treating liver diseases
|
|
CR20230472A
(es)
|
2021-03-10 |
2024-03-21 |
Dice Molecules Sv Inc |
Inhibidores de integrina alpha v beta 6 y alpha v beta 1 y sus usos
|
|
JP7644257B2
(ja)
|
2021-04-09 |
2025-03-11 |
中美華世通生物医薬科技（武漢）股▲ふん▼有限公司 |
Ｗｓ６３５薬物の使用
|
|
EP4326721A1
(de)
|
2021-04-22 |
2024-02-28 |
Protego Biopharma, Inc. |
Spirocyclische imidazolidinone und imidazolidindione zur behandlung von leichtkettiger amyloidose
|
|
WO2022251533A1
(en)
|
2021-05-27 |
2022-12-01 |
Protego Biopharma, Inc. |
Heteroaryl diamide ire1/xbp1s activators
|
|
WO2022266249A1
(en)
|
2021-06-16 |
2022-12-22 |
Biotheryx, Inc. |
Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
|
|
AU2022292649A1
(en)
|
2021-06-16 |
2024-01-04 |
Biotheryx, Inc. |
Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
|
|
WO2023044297A1
(en)
|
2021-09-14 |
2023-03-23 |
Impact Biomedicines, Inc. |
Fedratinib for treating myeloproliferative disorders
|
|
US12017997B2
(en)
|
2021-10-22 |
2024-06-25 |
Prosetta Biosciences, Inc. |
Host-targeted pan-respiratory antiviral small molecule therapeutics
|
|
WO2023102378A1
(en)
|
2021-11-30 |
2023-06-08 |
Kura Oncology, Inc. |
Macrocyclic compounds having farnesyltransferase inhibitory activity
|
|
US11932665B2
(en)
|
2022-01-03 |
2024-03-19 |
Lilac Therapeutics, Inc. |
Cyclic thiol prodrugs
|
|
EP4433040A4
(de)
|
2022-01-03 |
2025-11-12 |
Lilac Therapeutics Inc |
Acyclische thiol-prodrugs
|
|
JP2025507621A
(ja)
|
2022-03-02 |
2025-03-21 |
ミトパワー， インク． |
ニコチン酸及びリボースから誘導体化した新規プロドラッグ
|
|
GB2619907A
(en)
|
2022-04-01 |
2023-12-27 |
Kanna Health Ltd |
Novel crystalline salt forms of mesembrine
|
|
WO2023201282A1
(en)
|
2022-04-14 |
2023-10-19 |
Bristol-Myers Squibb Company |
Novel gspt1 compounds and methods of use of the novel compounds
|
|
TW202413356A
(zh)
|
2022-05-10 |
2024-04-01 |
美商拜歐斯瑞克斯公司 |
Ｃｄｋ蛋白降解劑、藥物組合物及其治療應用
|
|
CN120303264A
(zh)
|
2022-09-09 |
2025-07-11 |
医诺康治疗公司 |
CK1α和双重CK1α/GSPT1降解化合物
|
|
WO2024073473A1
(en)
|
2022-09-30 |
2024-04-04 |
Boulder Bioscience Llc |
Compositions comprising 3,3'-diindolylmethane for treating non-hemorrhagic closed head injury
|
|
EP4608838A1
(de)
|
2022-10-26 |
2025-09-03 |
Protego Biopharma, Inc. |
Spirocyclus mit pyridonverbindungen
|
|
WO2024092043A1
(en)
|
2022-10-26 |
2024-05-02 |
Protego Biopharma, Inc. |
Spirocycle containing pyridine compounds
|
|
EP4608839A1
(de)
|
2022-10-26 |
2025-09-03 |
Protego Biopharma, Inc. |
Spirocyclen mit bicyclischen heteroarylverbindungen
|
|
WO2024118810A1
(en)
|
2022-11-30 |
2024-06-06 |
Protego Biopharma, Inc. |
Cyclic pyrazole diamide ire1/xbp1s activators
|
|
WO2024118801A1
(en)
|
2022-11-30 |
2024-06-06 |
Protego Biopharma, Inc. |
Linear heteroaryl diamide ire1/xbp1s activators
|
|
AU2024316921A1
(en)
|
2023-07-28 |
2026-02-05 |
Sunshine Lake Pharma Co., Ltd. |
Substituted nitrogen-containing bicyclic compound and use thereof
|
|
WO2025063888A1
(en)
|
2023-09-19 |
2025-03-27 |
Kancure Pte. Ltd. |
Survivin-targeted compounds
|
|
US20250122182A1
(en)
|
2023-09-27 |
2025-04-17 |
Isosterix, Inc. |
MYST Inhibitors
|
|
WO2025072489A2
(en)
|
2023-09-27 |
2025-04-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Analogues of n-lactoyl-phenylalanine, methods of synthesis, and methods of use
|
|
WO2025085416A1
(en)
|
2023-10-16 |
2025-04-24 |
Bristol-Myers Squibb Company |
Gspt1 compounds and methods of use of the compounds
|
|
GB2636969A
(en)
|
2023-11-24 |
2025-07-09 |
Ontrack Therapeutics Ltd |
Novel crystalline salt forms
|
|
WO2025147691A1
(en)
|
2024-01-04 |
2025-07-10 |
Innovo Therapeutics, Inc. |
Compositions and methods for degrading aryl hydrocarbon receptor nuclear translocator protein
|
|
WO2025179161A1
(en)
|
2024-02-21 |
2025-08-28 |
Innovo Therapeutics, Inc. |
Protein degrading compounds
|
|
WO2025201633A1
(en)
|
2024-03-26 |
2025-10-02 |
Chen Gefei |
An agent for reducing amyloid formation
|
|
WO2025231261A1
(en)
|
2024-05-01 |
2025-11-06 |
Protego Biopharma, Inc. |
Bicyclic and heterocyclic amide compounds
|
|
WO2025255341A1
(en)
|
2024-06-05 |
2025-12-11 |
Protego Biopharma, Inc. |
Tetrahydrofuranyl ire1/xbp1s activators
|